Dude their revenues gave increased 100% since last quarter. They have plenty of money for all their operations for 2017. Their phase 3 study is underway and the drug is signifacantly improved liver cancer patients lives. Stop spreading vs bro we are sitting on a 16.00 stock. Near term 2.00 ..
Same type of pullback occurred from .0854 to .0412 ..just a 50% pullback. We have bottomed out institutional buyers are buying this play left and right. Insiders have not sold their shares oh by the way were purchased well over a dollar like a $1.25 based on the warrant info.
News 
Market Data 
Discover 
